HB 1689 – WashingtonStatus: Enacted
Year Introduced: 2022
Requires health plans to exempt biomarker testing for cancer or cancer progression or recurrence from prior authorization requirements.
Return to Database Search
© 2018-2019 The SLIHCQ Database. Initial funding for this project was provided by the Robert Wood Johnson Foundation. The views expressed here do not necessarily reflect the views of the Foundation.
No items found